VascVersa's ANGICYTE™ Technology provides a revolutionary Cell Therapy for blood vessel regeneration. It stimulates new blood vessel formation leading to improved blood supply & long term healing. This pipeline technology has the potential to be used for a number of ischaemic diseases. Our first product will provide a new therapeutic solution for the active wound care market.
VascVersa presents at the Inbound Investors
Christina presented at Inbound Investors. Inbound Investors took place at the Titanic Hotel in Belfast...
VascVersa collaborates with Hitech Health
VascVersa is delighted to partner with HiTech Health, Galway....
VascVersa secure Invest NI funding
VascVersa have been awarded Invest NI funding. This support from Invest NI will allow us to strengthen our Angicyte portfolio...
Cell therapies such as ANGICYTE™ technology that treat disease by regenerating tissue are at the forefront of medicine and are recognised as one of the world’s leading technologies that drive innovation and promote productivity and economic growth.
At VascVersa, we are committed to developing innovative regenerative medicine, to deliver a profound improvement to the lives of many individuals suffering from debilitating ischaemic diseases. In doing so we will address the urgent need for new treatments to repair damaged blood vessels and revitalise tissue.
Research & Drug Discovery
We have developed robust and consistent methodology to generate valuable human vascular reparative cells from a small sample of blood. Our unique method of generation produces highly pure and potent populations of ANGICYTE™ cells.
ANGICYTE™ creates stable blood vessels in vitro and in vivo. It can also provide a vital source of blood vessel cells for researchers studying angiogenesis or can be used to discover new drug therapies for cancer.